Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8846)	2/24/1999 7:33:00 PM
From: Bluegreen	Respond to of 17367

Does this mean, PAGE 2, that Paul Harvey will talk of Neuprex if it is approved for Meningitis or is the test more important? Or maybe if Neuprex is approved he will again bring up the test and Neuprex will be THE REST OF THE STORY! GOOD DAY!

To: aknahow who wrote (8846)	2/25/1999 8:08:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Found this........ Neisseria meningitidis is the leading infectious cause of death in childhood in the UK. There were over 2500 cases and 246 deaths in 1997 and the disease has an overall mortality of about 10%. Although mortality rises to 50% in the most severely ill patients, data from our unit suggests that early recognition, aggressive resuscitation, specialist advice, and transfer to paediatric intensive care can reduce this mortality to less than 5%.